Jian-Zhong Cao

Risk-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma: analysis from a multicenter study

Yong Yang, Yuan Zhu, Jian-Zhong Cao et al. · Blood · 2015 · 181 citations · Full text

Life Sciences, Immunology, Oncology +13

Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-making

Si-Ye Chen, Yong Yang, Shu‐Nan Qi et al. · Leukemia · 2020 · 131 citations · Full text

Medicine, Oncology, Cancer Immunology +13

Association of Improved Locoregional Control With Prolonged Survival in Early-Stage Extranodal Nasal-Type Natural Killer/T-Cell Lymphoma

Yong Yang, Jian-Zhong Cao, Shengmin Lan et al. · JAMA Oncology · 2016 · 83 citations

Medicine, Oncology, Radiation Oncology +16

First-line non–anthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma: a retrospective analysis from the CLCG

Shu‐Nan Qi, Yong Yang, Yu-Qin Song et al. · Blood Advances · 2020 · 57 citations · Full text

Medicine, Oncology, Cancer Immunology +12

Radiotherapy is essential after complete response to asparaginase-containing chemotherapy in early-stage extranodal nasal-type NK/T-cell lymphoma: A multicenter study from the China Lymphoma Collaborative Group (CLCG)

Xiu-Wen Deng, Jun-Xin Wu, Tao Wu et al. · Radiotherapy and Oncology · 2018 · 49 citations

Medicine, Oncology, Radiation Oncology +11